An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia

Asian Journal of Andrology

Volumn 13, Issue 4, 2011, Pages 630-635

  Jin, Zhe ^a   Zhang, Zhi Chao ^a   Liu, Ji Hong ^b   Lu, Jun ^c   Tang, Yu Xin ^d   Sun, Xiang Zhou ^e   Song, Wei Dong ^a   Gao, Bing ^a   Guo, Ying Lu ^a   Xin, Zhong Cheng ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

Author keywords

doxazosin GITS; erectile dysfunction; IPSS; lower urinary tract symptoms; quality of life; sildenafil

Indexed keywords

DOXAZOSIN; SILDENAFIL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHINESE; COMPARATIVE STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOXAZOSIN; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSTATIC HYPERPLASIA; PURINES; QUALITY OF LIFE; SULFONES; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 79960064163     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.177     Document Type: Article

References (22)

1. Zakaria L, Anastasiadis AG, Shabsigh R. Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression. Int Urol Nephrol 2001; 33: 283-92. (Pubitemid 34575375)
2. Oishi K, Boyle P, Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Proceedings of the Fourth International Consultation on BPH; 2-5 July 1997; Paris, France. Plymouth, , UK: Health Publications, 1998, pp23-59.
3. Glina S, Santana AW, Azank F, Mello LF, Moreira ED Jr. Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. BJU Int 2006; 97: 763-5. (Pubitemid 43383510)
4. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 2009; 73: 562-6.
5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61. (Pubitemid 24046934)
6. Taylor JM, DeSouza R, Wang R. Common approach to managing lower urinary tract symptoms and erectile dysfunction. Asian J Androl 2008; 10: 45-53.
7. Lee YC, Wu WJ, Liu CC, Wang CJ, Li WM et al. The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. J Sex Med 2009; 6: 3158-65.
8. Li MK, Garcia L, Patron N, Moh LC, Sundram M et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. BJU Int 2008; 101: 197-202. (Pubitemid 350294053)
9. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003; 44: 637-49. (Pubitemid 37542920)
10. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49: 436-42. (Pubitemid 32390877)
11. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia; 2003. Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 170 530-47
12. Uckert S, Kü the A, Jonas U. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90.
13. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2008; 53: 1320.
14. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T et al. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009; 6: 836-47.
15. Oger S, Behr-Roussel D, Gorny D, Lebret T, Denoux Y et al. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 2010; 57: 699-707.
16. de Rose AF, Giglio M, Traverso P, Lantieri P. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002; 14: 50-3. (Pubitemid 34188631)
17. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010; 75: 1452-8.
18. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A et al. Effects of oncedaily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727-35.
19. Uckert S, Sormes M, Kedia G, Scheller F, Knapp WH et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526-30. (Pubitemid 351374723)
20. Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging 2006; 1: 403-14.
21. McEvoy GK, editor. American Hospital Formulary Service Drug Information 2002. Bethesda, MD: American Society of Health System Pharmacists, Inc.; 2002 (Plus Supplements). p1819.
22. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172 (5 Pt 1)1935-40. (Pubitemid 39363095)